Published in Sci Transl Med on February 22, 2012
Using TRIPS flexibilities to facilitate access to medicines. Bull World Health Organ (2013) 1.04
Patents and misplaced angst: lessons for translational stem cell research from genomics. Cell Stem Cell (2013) 0.81
21(st) Century Cures Act: An Act of Cure or Diagnosis? Rejuvenation Res (2015) 0.78
Intellectual property policies in early-phase research in public-private partnerships. Nat Biotechnol (2016) 0.75
Public-Private Partnerships in Cloud-Computing Services in the Context of Genomic Research. Front Med (Lausanne) (2017) 0.75
A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron (2004) 5.71
Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol (2011) 4.67
Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 4.59
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation (2003) 2.77
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation (2012) 2.76
Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation (2003) 2.69
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest (2003) 2.27
Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem (2007) 2.10
Prostanoids in health and disease. J Lipid Res (2008) 2.06
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.97
DNA patents and diagnostics: not a pretty picture. Nat Biotechnol (2010) 1.95
COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol (2007) 1.77
Histone acetyltransferase-dependent chromatin remodeling and the vascular clock. J Biol Chem (2003) 1.77
COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res (2003) 1.72
Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med (2012) 1.71
Genetic components of the circadian clock regulate thrombogenesis in vivo. Circulation (2008) 1.62
Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A (2006) 1.52
Circadian clocks and vascular function. Circ Res (2010) 1.52
Parecoxib, valdecoxib, and cardiovascular risk. Circulation (2005) 1.51
Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation (2008) 1.50
Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol (2002) 1.49
Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci U S A (2002) 1.48
The missing ingredient in medicine patent pools. Lancet (2009) 1.43
Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci U S A (2009) 1.41
Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation (2005) 1.40
Bioinformatic analysis of circadian gene oscillation in mouse aorta. Circulation (2005) 1.40
COX-2-derived prostacyclin modulates vascular remodeling. Circ Res (2005) 1.37
The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol (2008) 1.36
EBP, a program for protein identification using multiple tandem mass spectrometry datasets. Mol Cell Proteomics (2006) 1.36
F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids (2004) 1.31
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology (2006) 1.27
Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med (2012) 1.22
Peripheral circadian clocks in the vasculature. Arterioscler Thromb Vasc Biol (2007) 1.20
Training translators for smart drug discovery. Sci Transl Med (2010) 1.19
Prostaglandin E synthases in zebrafish. Arterioscler Thromb Vasc Biol (2004) 1.16
Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nat Med (2006) 1.12
The role of clock genes in pharmacology. Annu Rev Pharmacol Toxicol (2010) 1.08
Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-activated receptor gamma activation. J Biol Chem (2007) 1.08
Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol (2005) 1.08
Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/MS/MS method. Methods Enzymol (2007) 1.07
Reduced nitric oxide causes age-associated impairment of circadian rhythmicity. Circ Res (2008) 1.06
Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. J Biol Chem (2006) 1.04
Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation (2010) 1.04
Genomics knowledge and equity: a global public goods perspective of the patent system. Bull World Health Organ (2004) 1.03
Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J Biol Chem (2007) 1.01
Terms and conditions: semantic complexity and aspirin resistance. Circulation (2004) 1.01
Prostaglandin F2alpha elevates blood pressure and promotes atherosclerosis. Proc Natl Acad Sci U S A (2009) 1.00
Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc Natl Acad Sci U S A (2012) 0.98
Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid. J Biol Chem (2007) 0.98
Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. J Clin Invest (2004) 0.97
Peripheral circadian clock rhythmicity is retained in the absence of adrenergic signaling. Arterioscler Thromb Vasc Biol (2007) 0.96
Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. J Virol (2004) 0.96
Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction? PLoS Med (2007) 0.95
Patent landscaping for life sciences innovation: toward consistent and transparent practices. Nat Biotechnol (2013) 0.93
Total synthesis of 8,12-iso-iPF3alpha-VI, an EPA-derived isoprostane: stereoselective introduction of the fifth asymmetric center. J Org Chem (2006) 0.92
Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: targeted exchange of cyclooxygenase isoforms in mice. Circ Res (2009) 0.92
Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1. Circulation (2012) 0.91
Gathering intelligence on antiplatelet drugs: the view from 30 000 feet. When combined with other information overviews lead to conviction. BMJ (2002) 0.90
Activation of nuclear receptors by prostaglandins. Thromb Res (2003) 0.90
Prostaglandin I₂promotes the development of IL-17-producing γδ T cells that associate with the epithelium during allergic lung inflammation. J Immunol (2011) 0.89
Human prostacyclin receptor. Vitam Horm (2002) 0.89
Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans. J Clin Invest (2012) 0.88
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. J Pharmacol Exp Ther (2012) 0.88
Eicosapentaenoic-acid-derived isoprostanes: synthesis and discovery of two major isoprostanes. Bioorg Med Chem Lett (2008) 0.86
Oxidized derivatives of omega-3 fatty acids: identification of IPF3 alpha-VI in human urine. J Lipid Res (2006) 0.86
Prostacyclin receptor signaling and early embryo development in the mouse. Hum Reprod (2007) 0.86
Total synthesis of isoprostanes: discovery and quantitation in biological systems. Chem Phys Lipids (2004) 0.86
Platelets, pyrexia, and plasmodia. N Engl J Med (2009) 0.85
Gene patents--more evidence needed, but policymakers must act. Nat Biotechnol (2007) 0.85
Biotechnology patents: strategies for meeting economic and ethical concerns. Nat Genet (2002) 0.84
Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice. Circulation (2014) 0.84
Knitting up the raveled sleave of care. Sci Transl Med (2013) 0.83
NCATS purrs: emerging signs of form and function. Sci Transl Med (2011) 0.82
Cardiovascular biology of microsomal prostaglandin E synthase-1. Trends Cardiovasc Med (2010) 0.82
Niacin, an old drug with a new twist. J Lipid Res (2013) 0.81
Role of thromboxane receptor in C-reactive protein-induced thrombosis. Arterioscler Thromb Vasc Biol (2012) 0.80
A prospective analysis of oxidative stress and liver transplantation. Transplantation (2002) 0.79
Guest authorship, mortality reporting, and integrity in rofecoxib studies. JAMA (2008) 0.79
Genomic organization of the rat Clock gene and sequence analysis in inbred rat strains. Genomics (2006) 0.79
Deletion of microsomal prostaglandin E synthase-1 does not alter ozone-induced airway hyper-responsiveness. J Pharmacol Exp Ther (2010) 0.78
PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics (2015) 0.78
Between a rock and a hard place: how to align our circadian rhythms? Circulation (2012) 0.78
Isoprostane activation of the nuclear hormone receptor PPAR. Adv Exp Med Biol (2002) 0.77
(Almost) everything is illuminated: adenosine shines a light on cardioprotection. Circ Res (2012) 0.77
iPF2alpha-III-17,18,19,20-d4: total synthesis and metabolism. Bioorg Med Chem Lett (2005) 0.77
Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury. Circ Res (2012) 0.77
Activation-dependent internalization of the human prostacyclin receptor. Adv Exp Med Biol (2002) 0.77
Platelet microRNAs: Novy Mir* or mired in human complexity? Circ Res (2013) 0.76
Functionalized low-density lipoprotein nanoparticles for in vivo enhancement of atherosclerosis on magnetic resonance images. Bioconjug Chem (2012) 0.76
PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics (2015) 0.75
"What great creation". Interview by Alisa M. Clyne. Sci Transl Med (2012) 0.75
A rattle bag of science and the art of translation. Sci Transl Med (2011) 0.75
Enabling advanced cell therapies (EnACT): invitation to an online forum on resolving barriers to clinical translation. Regen Med (2012) 0.75